Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 10-day prospective, single-center, double-blind, placebo-controlled, randomized study to evaluate safety, tolerability and pharmacokinetics of 600 mg b.i.d. oral doses of LM11A-31-BHS in healthy elderly volunteers

Next Previous
Trial Profile

A 10-day prospective, single-center, double-blind, placebo-controlled, randomized study to evaluate safety, tolerability and pharmacokinetics of 600 mg b.i.d. oral doses of LM11A-31-BHS in healthy elderly volunteers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LM 11A-31 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Sponsors PharmatrophiX

Most Recent Events

  • 07 Oct 2024 According to a Alzheimer's Drug Discovery Foundation media release, trial data will be showcased with PharmatophiX on Thursday, October 31st at 2024 Clinical Trials on Alzheimer's Disease Conference.
  • 03 Nov 2021 According to a Alzheimer's Drug Discovery Foundation media release, an analysis from this trial will be presented at the 14th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD), 2021.
  • 22 May 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top